Physician profile
Jonathan Umbel
NPI 1831485028
$4,646.88
in general payments reported to CMS, 2019-2025
26 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $137 · 2021: $202 · 2022: $351 · 2023: $657 · 2024: $1,072 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,075.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.21 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $686.72 | 2019-2025 | Tremfya, Stelara |
| Medtronic, INC. | $505.80 | 2023-2025 | Eea |
| Madrigal Pharmaceuticals | $341.68 | 2024-2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.07 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $171.38 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $126.28 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $124.28 | 2020 | |
| Celgene Corporation | $71.80 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $68.54 | 2022-2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.12 | 2023-2024 | Cyltezo |
| Organon LLC | $59.65 | 2023 | Renflexis, Hadlima |
| Qol Medical, LLC | $57.78 | 2023 | Sucraid |
| Steris Corporation | $51.42 | 2025 | |
| Pfizer INC. | $47.29 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46.47 | 2024-2025 | |
| Lilly USA, LLC | $43.87 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $43.76 | 2021-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $34.96 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $34.34 | 2024 | Dupixent |
| Alexion Pharmaceuticals, INC. | $16.67 | 2021 | |
| Braintree Laboratories, INC. | $15.36 | 2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $14.93 | 2024 | |
| Ardelyx, INC. | $14.18 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $14.14 | 2023 | Rebyota |
| Allergan, INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Umbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.